Abstract
Zoledronic acid (Aclasta - Novartis) is the first bisphosphonate to be licensed in the UK as a once-yearly intravenous treatment for women with postmenopausal osteoporosis. Promotional materials claim that the drug "provides powerful osteoprotection with yearlong compliance", with "significant 3 year fracture reduction at all key sites". Here we consider whether zoledronic acid has a role in the treatment of women with postmenopausal osteoporosis.
MeSH terms
-
Aged
-
Bone Density Conservation Agents / administration & dosage*
-
Bone Density Conservation Agents / adverse effects
-
Bone Density Conservation Agents / economics
-
Diphosphonates / administration & dosage*
-
Diphosphonates / adverse effects
-
Diphosphonates / economics
-
Drug Administration Schedule
-
Drug Costs
-
Female
-
Hip Fractures / rehabilitation
-
Hip Fractures / surgery
-
Humans
-
Imidazoles / administration & dosage*
-
Imidazoles / adverse effects
-
Imidazoles / economics
-
Infusions, Intravenous
-
Osteoporosis, Postmenopausal / drug therapy*
-
Osteoporosis, Postmenopausal / economics
-
Postoperative Care
-
Randomized Controlled Trials as Topic
-
Zoledronic Acid
Substances
-
Bone Density Conservation Agents
-
Diphosphonates
-
Imidazoles
-
Zoledronic Acid